ArticleMetrologia2025
Primary activity measurement of an Am-241 solution using microgram inkjet gravimetry and decay energy spectrometry.
Article in Metrologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
We demonstrate a method for radionuclide assay that is spectroscopic with 100 % counting efficiency for alpha decay. Advancing both cryogenic decay energy spectrometry (DES) and drop-on-demand inkjet metrology, a solution of Am-241 was assayed for massic activity (of order 100 kBq/g) with a relative combined standard uncertainty less than 1 %. We implement live-timed counting, spectroscopic analysis, validation by liquid scintillation (LS) counting, and confirmation of quantitative solution transfer. Experimental DES spectra are well modeled with a Monte Carlo simulation. The model was further used to simulate Pu-238 and Pu-240 impurities, calculate detection limits, and demonstrate the potential for tracer-free multi-nuclide analysis, which will be valuable for new cancer therapeutics based on decay chains, Standard Reference Materials (SRMs) containing impurities, and more widely in nuclear energy, environmental monitoring, security, and forensics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.